Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Sulanda (surufatinib)
i
Other names:
HMPL-012, HMPL012, HMPL 012
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(7)
News
Trials
Company:
Hutchmed
Drug class:
VEGFR inhibitor, FGFR1 inhibitor
Related drugs:
‹
sunitinib (139)
lenvatinib (90)
axitinib (34)
fruquintinib (24)
cediranib (9)
TKI258 (9)
MGCD265 (4)
E 3810 (4)
OMP-305B83 (3)
ABT-869 (2)
DC101 (1)
vorolanib (1)
CS 2164 (1)
KD019 (1)
BMS690514 (0)
CVX-241 (0)
ESK981 (0)
adAptVEGF-C adenoviral vector (0)
SU 14813 (0)
SYHA1813 (0)
VEGFR1-1084 (0)
ABT-165 (0)
IMC-18F1 (0)
ABT348 (0)
PI-88 (0)
SU5416 (0)
GS 6624 (0)
BAY 57- 9352 (0)
RG7221 (0)
PTK787 (0)
erdafitinib (70)
Max-40279 (2)
amlexanox (1)
HMPL-453 (1)
TT-00434 (1)
BMS-582664 (1)
ASP5878 (0)
FP-1039 (0)
HH185 (0)
LY2874455 (0)
OM-RCA-01 (0)
R1530 (0)
S-49076 (0)
SKI-G-801 (0)
sunitinib (139)
lenvatinib (90)
axitinib (34)
fruquintinib (24)
cediranib (9)
TKI258 (9)
MGCD265 (4)
E 3810 (4)
OMP-305B83 (3)
ABT-869 (2)
DC101 (1)
vorolanib (1)
CS 2164 (1)
KD019 (1)
BMS690514 (0)
CVX-241 (0)
ESK981 (0)
adAptVEGF-C adenoviral vector (0)
SU 14813 (0)
SYHA1813 (0)
VEGFR1-1084 (0)
ABT-165 (0)
IMC-18F1 (0)
ABT348 (0)
PI-88 (0)
SU5416 (0)
GS 6624 (0)
BAY 57- 9352 (0)
RG7221 (0)
PTK787 (0)
erdafitinib (70)
Max-40279 (2)
amlexanox (1)
HMPL-453 (1)
TT-00434 (1)
BMS-582664 (1)
ASP5878 (0)
FP-1039 (0)
HH185 (0)
LY2874455 (0)
OM-RCA-01 (0)
R1530 (0)
S-49076 (0)
SKI-G-801 (0)
›
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
surufatinib
Sensitive: A1 - Approval
surufatinib
Sensitive
:
A1
surufatinib
Sensitive: A1 - Approval
surufatinib
Sensitive
:
A1
PD-L1 underexpression
Gastric Adenocarcinoma
PD-L1 underexpression
Gastric Adenocarcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 expression
Neuroendocrine Tumor
PD-L1 expression
Neuroendocrine Tumor
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login